Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation

By C. Cannon, Deepak L. Bhatt, J. Oldgren, Gregory Y. H. Lip, S. Ellis, Takeshi Kimura, M. Maeng, B. Merkely, U. Zeymer, S. Gropper and 8 more. New England Journal of Medicine, 2017

1,163 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/5cdd13229383c669a9909e766410bab0e80d0858

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. A. Goette

Citations in the corpus

• The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. (2018, methodology): “dual therapy, without aspirin) were compared with standard triple therapy (for 1 or 3 months depending on the type of stent) with VKA, aspirin, and either clopidogrel or ticagrelor in 2725 patients with AF undergoing PCI.(141) The composite of major or clinical relevant nonmajor bleeding events and ”